GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment

Dateline City:

LONDON & KENILWORTH, N.J.

Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)

LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced
the initiation of a phase I clinical trial designed to evaluate GSK’s
investigational immunotherapy GSK3174998 as monotherapy and in
combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)
in patients with locally advanced, recurrent or metastatic solid
tumour(s) that have progressed after standard treatment.

Language:

English

Contact:

MerckMedia Relations:Pamela Eisele, [phone]orAn Phan, [phone]orInvestor Relations:Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Product News - November 3, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news